(function(){
			var content_array=["<p><b>关于非小细胞肺癌（<\/b><b>NSCLC）<\/b><\/p> \n<p>肺癌是全球致死率最高的一类恶性肿瘤，<sup>[6]<\/sup>预计到2040年全球发病数将突破300万例。<sup>[7]<\/sup>其中，非小细胞肺癌（NSCLC）是最常见的病理类型。<sup>[8]<\/sup>该疾病确诊时通常已届晚期，<sup>[9]<\/sup>患者5年生存率不足30%。<sup>[10]<\/sup>晚期非小细胞肺癌（NSCLC）患者往往承受着身体机能衰退、心理创伤和情绪困扰等多重打击，生活质量因而大打折扣。现阶段，晚期非小细胞肺癌（NSCLC）患者仍存在巨大的未满足需求。值得注意的是，多达4%的肺癌病例由HER2基因突变（或变异）驱动。<sup>[11]<\/sup>HER2基因突变会导致过度表达与过度激活，进而引发细胞增殖失控、抑制细胞死亡，最终诱导肿瘤生长、癌细胞扩散。<\/p> \n<p><b>关于勃林格殷格翰在肿瘤学领域 <\/b><\/p> \n<p>勃林格殷格翰致力于推动具有深远意义的科学进步，为癌症患者生活带来变革，最终实现治愈各类癌症。公司世世代代推动科学创新的承诺，在稳健的癌细胞靶向与免疫肿瘤学在研疗法产品线，以及巧妙的联合疗法策略中得到生动体现。在肿瘤学领域，勃林格殷格翰矢志不渝地构建广泛合作研究网络，积极寻求多元化的创新思路，这对于攻克极具挑战且影响巨大的癌症研究领域至关重要。简而言之，对于勃林格殷格翰，攻克癌症关乎当前和未来的世世代代。<\/p> \n<p><b>关于勃林格殷格翰与中国生物制药的战略合作<\/b><\/p> \n<p>勃林格殷格翰与中国生物制药建立战略合作伙伴关系，致力于为中国大陆市场带来创新的肿瘤疗法。此次合作将凭借双方的互补优势，为中国的癌症患者提供更多更好的治疗方案。双方将合作勃林格殷格翰多个处于临床开发晚期阶段的创新肿瘤产品。宗艾替尼是勃林格殷格翰和中国生物制药在中国大陆的战略合作产品之一。<\/p> \n<div> \n <table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\"> \n  <tbody> \n   <tr> \n    <td class=\"prnpr2 prnpl2 prnsbtb1 prnrbrb1 prnsbbb1 prnsblb1\" colspan=\"1\" rowspan=\"1\"><p class=\"prnml4\"><span class=\"prnews_span\">[1] HERNEXEOS Prescribing Information<br \/>[2] Heymach, J. et al. Zongertinib in previously treated HER2-mutant non-small cell lung cancer. N Engl J Med. 2025;01-13.<br \/>[3] Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906.<br \/>[4] Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51<br \/>[5] Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. J Natl Cancer Cent. 2021 May 3;1(2):58-73.<br \/>[6] World Health Organization Cancer Factsheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer (Accessed April 2025).<br \/>[7] International Agency for Research on Cancer – World Health Organization. Rates of trachea, bronchus and lung cancer. Available at: https:\/\/gco.iarc.fr\/tomorrow\/en (Accessed August 2024).<br \/>[8] Zappa C &amp; Mousa Non-small cell lung cancer: current treatment and future advances, Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300.<br \/>[9] Polanco D et al. Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study. J Thorac Dis 2021;13:1485–1494<br \/>[10] National Cancer Institute Surveillance, Epidemiology, and End Results (SEER). https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html (Accessed: August 2024).<br \/>[11] Arcila, M. E. et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. cancer Res.&nbsp; an Off. J. Am. Assoc.&nbsp; Cancer Res. 18, 4910–4918 (2012).<\/span><\/p> <\/td> \n   <\/tr> \n  <\/tbody> \n <\/table> \n<\/div> \n<p>&nbsp;<\/p>"];
			$("#dvExtra").html(content_array[0]);})();